Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2016 | original article | Ausgabe 17-18/2016 Open Access

Wiener klinische Wochenschrift 17-18/2016

Management of malignant pleural mesothelioma – part 3

Data from the Austrian Mesothelioma Interest Group (AMIG) database

Wiener klinische Wochenschrift > Ausgabe 17-18/2016
Thomas Klikovits, Assist. Prof. Dr. Mir Alireza Hoda, Yawen Dong, Madeleine Arns, Bernhard Baumgartner, Peter Errhalt, Christian Geltner, Barbara Machan, Wolfgang Pohl, Jörg Hutter, Josef Eckmayr, Michael Studnicka, Martin Flicker, Peter Cerkl, Klaus Kirchbacher, Walter Klepetko
Wichtige Hinweise
All authors contribute on behalf of the Austrian Mesothelioma Interest Group (AMIG).



Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor originating from the pleural cavity with a strong link to previous asbestos exposure. In order to determine the demographics, diagnostics, therapeutic strategies, and prognosis of MPM patients in Austria, the Austrian Mesothelioma Interest Group (AMIG) was founded in 2011. In this report the data from the AMIG MPM database collected to date are reported.


A prospective observational registry was initiated, including patients with histologically verified MPM diagnosed and treated at specialized centers in Austria. Patient inclusion started in January 2011 and follow-up was completed until September 2015.


A total number of 210 patients were included. There were 167 male and 43 female patients with a mean age of 67.0 years (SD ± 11.3) at the time of diagnosis. Asbestos exposure was confirmed in 109 (69.4 %) patients. The histological subtype was epithelioid in 141 (67.2 %), sarcomatoid in 16 (7.6 %), biphasic in 28 (13.3 %), and MPM not otherwise specified in 25 (11.9 %) patients. Of the patients, 30 (14.3 %) received best supportive care (BSC) only, 71 (33.8 %) chemotherapy (CHT) alone, four (1.9 %) radiotherapy (RT) alone, 23 (11.9 %) CHT/RT, two (0.9 %) surgery alone, and 76 (36.2 %) curative surgery within a multimodality treatment (MMT), which was more frequently performed for patients younger than 65 years and with early-stage disease (I + II). Median overall survival (OS) was 19.1 months (95 % CI 14.7–23.5). The 1‑, 3‑, and 5‑year OS rates were 66 %, 30 %, and 23 %, respectively, and OS was significantly better in patients undergoing surgery within MMT (5-year survival 5 % vs. 40 %, p = 0.001).


Patients with earlier disease stages, younger age, good performance status, and epithelioid histology were more likely to undergo MMT including surgery, which resulted in a more favorable outcome.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 17-18/2016

Wiener klinische Wochenschrift 17-18/2016 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Wiener Klinische Wochenschrift 15/16 2016 – Inhalte